Dechra Pharmaceuticals PLC Logo

Dechra Pharmaceuticals PLC

Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.

DPH | IL

Overview

Corporate Details

ISIN(s):
US2434351043
LEI:
213800J4UVB5OWG8VX82
Country:
United Kingdom
Address:
24 CHESHIRE AVENUE, CW9 7UA NORTHWICH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dechra Pharmaceuticals PLC is a global specialist in veterinary pharmaceuticals and related products. The company focuses on the development, manufacture, marketing, and sales of high-quality products designed to improve animal health and welfare. Its portfolio includes a range of drugs and therapies for the prevention, diagnosis, and treatment of conditions in animals, with a focus on companion animals like dogs, cats, and horses. Dechra markets its products exclusively to veterinarians worldwide, positioning itself as a dedicated partner to the profession. The company also provides educational support through resources like the Dechra Academy to help veterinary professionals stay current with industry advancements.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-23 17:41
Major Shareholding Notification
Holding(s) in Company
English 23.4 KB
2024-01-18 16:14
Major Shareholding Notification
Holding(s) in Company
English 21.7 KB
2024-01-18 11:11
Major Shareholding Notification
Holding(s) in Company
English 26.8 KB
2024-01-17 15:01
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-17 13:01
Delisting Announcement
Holding(s) in Company
English 51.4 KB
2024-01-17 13:00
Major Shareholding Notification
Holding(s) in Company
English 54.9 KB
2024-01-17 12:16
Major Shareholding Notification
Holding(s) in Company
English 29.1 KB
2024-01-17 09:15
Delisting Announcement
Cancellation of listing and admission to trading
English 24.9 KB
2024-01-17 08:30
Major Shareholding Notification
Holding(s) in Company
English 21.6 KB
2024-01-16 17:54
Major Shareholding Notification
Holding(s) in Company
English 22.5 KB
2024-01-16 16:25
Major Shareholding Notification
Form 8.3 - Dechra Pharmaceuticals plc
English 46.1 KB
2024-01-16 15:43
Major Shareholding Notification
Holding(s) in Company
English 31.2 KB
2024-01-16 13:04
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-16 11:15
AGM Information
Scheme of Arrangement becomes Effective
English 45.8 KB
2024-01-16 10:00
Major Shareholding Notification
Holding(s) in Company
English 29.7 KB

Automate Your Workflow. Get a real-time feed of all Dechra Pharmaceuticals PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dechra Pharmaceuticals PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dechra Pharmaceuticals PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Epitomee Medical Ltd. Logo
Develops ingestible therapeutic devices for weight management and targeted drug delivery.
Israel
EPIT
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.